Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 19/20 | 0.61 |
| ▸ | PLK2 | Q9NYY3 | 17/20 | 0.61 |
| ▸ | PLK3 | Q9H4B4 | 15/20 | 0.61 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | TAF1 | P21675 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17884568 | 0.87 | PLK1 (0.62) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL2032200 | 0.86 | PLK1 (0.69) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL2032197 | 0.86 | PLK1 (0.69) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL376094 | 0.86 | PLK1 (0.61) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL10320062 | 0.86 | PLK1 (0.61) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL1527197 | 0.86 | PLK1 (0.61) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL6840444 | 0.86 | PLK1 (0.61) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL15267472 | 0.84 | PLK1 (0.59) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL6840311 | 0.83 | PLK1 (0.58) | PLK1PLK2PLK3BRD4TAF1 | |
| SCHEMBL2339739 | 0.83 | PLK1 (0.66) | PLK1PLK2PLK3BRD4TAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8138341-B2 | Intermediate compounds useful for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-20 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | PLK1 1/4885PLK2 22/4885PLK3 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.